InvestorsObserver
×
News Home

Unicycive Therapeutics Inc (UNCY) has risen 10.19% in a Week, Should You Hold?

Thursday, March 16, 2023 10:14 AM | InvestorsObserver Analysts

Mentioned in this article

Unicycive Therapeutics Inc (UNCY) has risen 10.19% in a Week, Should You Hold?

The 90 rating InvestorsObserver gives to Unicycive Therapeutics Inc (UNCY) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 100 percent of stocks in the Biotechnology industry, UNCY’s 90 overall rating means the stock scores better than 90 percent of all stocks.

Overall Score - 90
UNCY has an Overall Score of 90. Find out what this means to you and get the rest of the rankings on UNCY!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.
These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With Unicycive Therapeutics Inc Stock Today?

Unicycive Therapeutics Inc (UNCY) stock has risen 2.71% while the S&P 500 is down -0.22% as of 10:13 AM on Thursday, Mar 16. UNCY has risen $0.06 from the previous closing price of $2.21 on volume of 333,716 shares. Over the past year the S&P 500 has fallen -10.89% while UNCY has risen 104.50%. UNCY lost -$1.03 per share the over the last 12 months. Click Here to get the full Stock Report for Unicycive Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App